Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China

Zheng,Jianhua; Yin,Qianqian; Cao,Juanyi; Zhang,Bei

doi:10.3892/etm.2017.4094

Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20-38 years in China

Authors:
- Jianhua Zheng
- Qianqian Yin
- Juanyi Cao
- Bei Zhang
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Xuzhou Central Hospital Affiliated to Southeast University, Xuzhou, Jiangsu 221009, P.R. China, Center for Reproductive Medicine, Xuzhou Central Hospital Affiliated to Southeast University, Xuzhou, Jiangsu 221009, P.R. China
Published online on: January 31, 2017 https://doi.org/10.3892/etm.2017.4094
Pages: 1337-1342
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We investigated the association between the apolipoprotein B (ApoB)/apolipoprotein A1 (ApoA1) ratio and insulin resistance (IR), metabolic syndrome (MS) and its components in Chinese polycystic ovary syndrome (PCOS) adults. We also examined whether hyperandrogenism is involved in obesity-related metabolic abnormalities in a cohort of patients. A clinical cross-sectional study consisting of 532 Chinese PCOS adults aged 20-38 years was designed. Each subject underwent a physical examination and laboratory evaluation. We found that the ApoB/ApoA1 ratio was signiﬁcantly higher in patients with MS compared to those without MS. This test provided 83.6% sensitivity and 67.6% specificity with a threshold value of 0.60 in MS. The ApoB/ApoA1 ratio increased signiﬁcantly as the number of MS components increased. After adjusting for age, the patients with MS or IR were more likely to be in the high ApoB/ApoA1 group, and the ApoB/ApoA1 ratio was associated signiﬁcantly with each of the MS components, high free testosterone (FT), and high free androgen index (FAI). After adjusting for age and body mass index (BMI), the association persisted for all factors excluding high blood pressure (BP), high fasting plasma glucose (FPG), high FT, and high FAI. Therefore, the ApoB/ApoA1 ratio was strongly associated with IR, MS and its components, high FT, and high FAI. A high ApoB/ApoA1 ratio appears to be a good predictive marker of MS in Chinese PCOS adults. Obesity, especially central obesity, contributes more to increasing ApoB/ApoA1 ratio than increased BP, FPG, FT and FAI in this cohort of PCOS patients.

View Figures

View References

1	Hamilton CA: Low-density lipoprotein and oxidised low-density lipoprotein: their role in the development of atherosclerosis. Pharmacol Ther. 74:55–72. 1997. View Article : Google Scholar : PubMed/NCBI
2	Barter PJ and Rye KA: The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med. 259:447–454. 2006. View Article : Google Scholar : PubMed/NCBI
3	Faraj M, Messier L, Bastard JP, Tardif A, Godbout A, Prud'homme D and Rabasa-Lhoret R: Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women. Diabetologia. 49:1637–1646. 2006. View Article : Google Scholar : PubMed/NCBI
4	Franks S: Polycystic ovary syndrome. N Engl J Med. 333:853–861. 1995. View Article : Google Scholar : PubMed/NCBI
5	Maitra A, Pingle RR, Menon PS, Naik V, Gokral JS and Meherji PK: Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women. Int J Fertil Womens Med. 46:271–277. 2001.PubMed/NCBI
6	Sniderman AD, Blank D, Zakarian R, Bergeron J and Frohlich J: Triglycerides and small dense LDL: The twin Achilles heels of the Friedewald formula. Clin Biochem. 36:499–504. 2003. View Article : Google Scholar : PubMed/NCBI
7	Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD and Sniderman AD: The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 42:1355–1363. 2004. View Article : Google Scholar : PubMed/NCBI
8	McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, et al: INTERHEART study investigators: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 372:224–233. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yin Q, Chen X, Li L, Zhou R, Huang J and Yang D: Apolipoprotein B/apolipoprotein A1 ratio is a good predictive marker of metabolic syndrome and pre-metabolic syndrome in Chinese adolescent women with polycystic ovary syndrome. J Obstet Gynaecol Res. 39:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
10	Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 81:19–25. 2004. View Article : Google Scholar
11	Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES and Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 89:2745–2749. 2004. View Article : Google Scholar : PubMed/NCBI
12	Hatch R, Rosenfield RL, Kim MH and Tredway D: Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 140:815–830. 1981. View Article : Google Scholar : PubMed/NCBI
13	International Diabetes Federation, . The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/Metabolic_syndrome_definition.pdfAccessed. July 10–2008.
14	World Health Organization, . Measuring obesity: classification and description of anthropometric data: report on a WHO consultation on the epidemiology of obesity. Warsaw, 21–23 October 1987. World Health Organization; Copenhagen: 1989
15	Chen X, Yang D, Li L, Feng S and Wang L: Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod. 21:2027–2032. 2006. View Article : Google Scholar : PubMed/NCBI
16	Sung KC and Hwang ST: Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis. 180:161–169. 2005. View Article : Google Scholar : PubMed/NCBI
17	Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, Hellénius ML and Fisher RM: ApoB/apoA-I ratio: αn independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 28:2637–2643. 2007. View Article : Google Scholar : PubMed/NCBI
18	Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF and Adeli K: Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem. 275:8416–8425. 2000. View Article : Google Scholar : PubMed/NCBI
19	Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le-Tien H, Fantus IG, Lewis GF and Adeli K: Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. J Biol Chem. 277:793–803. 2002. View Article : Google Scholar : PubMed/NCBI
20	Jing F, Mao Y, Guo J, Zhang Z, Li Y, Ye Z, Ding Y, Wang J, Jin M and Chen K: The value of Apolipoprotein B/Apolipoprotein A1 ratio for metabolic syndrome diagnosis in a Chinese population: a cross-sectional study. Lipids Health Dis. 13:812014. View Article : Google Scholar : PubMed/NCBI
21	Erdeve S Savas, Simsek E, Dallar Y and Biyikli Z: Utility of ApoB/ApoA1 ratio for the prediction of cardiovascular risk in children with metabolic syndrome. Indian J Pediatr. 77:1261–1265. 2010. View Article : Google Scholar : PubMed/NCBI
22	Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J and Fagerberg B: Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke. 35:2248–2252. 2004. View Article : Google Scholar : PubMed/NCBI
23	Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS and Lopez-Jimenez F: Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol. 98:1369–1373. 2006. View Article : Google Scholar : PubMed/NCBI
24	Zhong L, Li Q, Jiang Y, Cheng D, Liu Z, Wang B, Luo R, Cheng Q and Qing H: The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population. Inflammation. 33:353–358. 2010. View Article : Google Scholar : PubMed/NCBI
25	Haffner SM, Kushwaha RS, Foster DM, Applebaum-Bowden D and Hazzard WR: Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 32:413–420. 1983. View Article : Google Scholar : PubMed/NCBI
26	Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC and Gooren LJ: Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf). 58:562–571. 2003. View Article : Google Scholar : PubMed/NCBI